GlassScriptPhysician profile
Albert L Vanamburg
NPI 1306804489
$3,035.01
in general payments reported to CMS, 2019-2025
41 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $63.91 · 2022: $30.54 · 2023: $679 · 2024: $1,304 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.26 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $375.08 | 2019-2025 | |
| Pfizer INC. | $217.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $202.38 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Celgene Corporation | $196.56 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $182.09 | 2019-2025 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $165.12 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Incyte Corporation | $164.13 | 2023-2024 | Pemazyre, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $140.74 | 2019-2024 | Injectafer, Enhertu |
| Janssen Biotech, INC. | $133.02 | 2019-2024 | Darzalex, Tecvayli, Talvey |
| Eisai INC. | $109.24 | 2023-2025 | |
| Emd Serono, INC. | $92.68 | 2022-2024 | Bavencio |
| Genentech USA, INC. | $89.46 | 2019-2024 | Lunsumio, Polivy, Columvi |
| Takeda Pharmaceuticals U.S.A., INC. | $85.79 | 2023-2024 | Iclusig, Fruzaqla, Alunbrig |
| Regeneron Healthcare Solutions, INC. | $79.87 | 2023-2025 | Libtayo |
| Amgen INC. | $77.24 | 2019-2024 | Blincyto, Kyprolis, Evenity |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58.19 | 2024-2025 | |
| Puma Biotechnology, INC. | $48.20 | 2019-2024 | |
| Glaxosmithkline, LLC. | $45.37 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Karyopharm Therapeutics INC. | $44.91 | 2024 | Xpovio |
| Gilead Sciences, INC. | $38.81 | 2019-2025 | Trodelvy |
| Tersera Therapeutics LLC | $37.61 | 2024 | Zoladex |
| Taiho Oncology, INC. | $37.60 | 2024 | |
| Pharmacosmos Therapeutics INC. | $37.03 | 2025 | Monoferric |
| Servier Pharmaceuticals LLC | $36.65 | 2023-2024 | |
| Kite Pharma, INC. | $30.15 | 2023 | Yescarta |
| Astellas Pharma US INC | $29.48 | 2024 | Padcev, Xtandi |
| Exelixis INC. | $22.99 | 2024 | Cabometyx |
| Coherus Oncology, INC. | $21.97 | 2020 | |
| Jazz Pharmaceuticals INC. | $21.19 | 2024 | |
| Sobi, INC | $21.07 | 2024 | |
| Genzyme Corporation | $20.24 | 2019 | |
| Fennec Pharmaceuticals, INC. | $20.04 | 2024 | Pedmark |
| Lilly USA, LLC | $19.77 | 2023 | Retevmo, Verzenio, Jaypirca |
| Octapharma USA, INC. | $18.84 | 2024 | Octagam Immune Globulin (Human) |
| Bayer Healthcare Pharmaceuticals INC. | $18.48 | 2019 | |
| Tesaro, INC. | $18.31 | 2019 | |
| Kyowa Kirin, INC. | $18.03 | 2024 | Poteligeo |
| Stemline Therapeutics INC. | $15.99 | 2023 | Orserdu |
| Verastem, INC. | $15.33 | 2019 | |
| Array Biopharma INC | $14.90 | 2025 | Tukysa, Braftovi, Mektovi |
| Cti Biopharma Corp. | $13.07 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Vanamburg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.